Wednesday, July 8, 2026

pharma · Chronic Lymphocytic Leukemia · Relapsing Multiple Sclerosis · TGTX

TG THERAPEUTICS

TG THERAPEUTICS clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US HQ
2011 Founded
521 Employees
Public company Type
TGTX · NYSE Ticker
Company details
Status
Public
HQ
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US
Founded
2011
Employees
521
Programs
39
Drugs
23
Patents
7
Intelligence · Clinical Programs

TG THERAPEUTICS projects

13 ClinicalTrials.gov programs sponsored by TG THERAPEUTICS.

TG THERAPEUTICS has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Acalabrutinib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial
  2. Pembrolizumab

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 2 mab terminated

    1 trial
  3. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial
  4. TGR-1202

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial
  5. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Remitting Multiple Sclerosis

    phase 2 mab completed

    1 trial
  6. Ublituximab

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial
  7. Ublituximab

    TG THERAPEUTICS, INC.

    multiple sclerosis

    phase 2 small molecule active

    1 trial
  8. Ublituximab

    TG THERAPEUTICS, INC.

    Autoimmune Disorders

    phase 2 small molecule active

    1 trial
  9. Ublituximab

    TG THERAPEUTICS, INC.

    Non-Hodgkins Lymphoma

    phase 2 small molecule completed

    2 trials
  10. Umbralisib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule completed

    4 trials
  11. Umbralisib

    TG THERAPEUTICS, INC.

    Lymphoma

    phase 2 small molecule terminated

    1 trial
  12. Umbralisib

    TG THERAPEUTICS, INC.

    Marginal Zone Lymphoma

    phase 2 small molecule completed

    1 trial
  13. Venetoclax

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does TG THERAPEUTICS have?

13 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.